Glycosaminoglycan-Based CD44-Targeted Nanoparticles for Cancer Therapy: Biological Barriers and Barrier-Informed Design Strategies.

Authors

Shangyu Chen, Sheida Dabiri, Yichen Xu, Song Li

Published in

Nano letters. Volume 26. Issue 43. Pages 14803-14812. Nov 04, 2026.

Abstract

Nanoparticle (NP)-based drug delivery has been explored to improve the therapeutic index of anticancer agents by enhancing tumor accumulation and reducing systemic toxicity. Among active targeting approaches, cluster of differentiation 44 (CD44) has attracted attention because of its overexpression in tumor cells and tumor-associated endothelial cells and its involvement in tumor progression and therapeutic resistance. Hyaluronic acid (HA) and other glycosaminoglycan (GAG)-based nanocarriers have been developed to exploit CD44-mediated tumor targeting and cellular uptake. However, the in vivo performance of CD44-targeted NPs remains variable because of barriers such as systemic clearance, heterogeneous tumor vasculature and stroma, limited receptor accessibility, competition with endogenous ligands, and inefficient intracellular trafficking or payload release. This Letter summarizes advances in CD44-targeted NP delivery, focusing on barriers at systemic, tumor tissue, and cellular levels. We discuss barrier-informed strategies to optimize ligand presentation, improve penetration, promote intracellular payload release, and highlight translational challenges and opportunities for CD44-targeted nanomedicines.

PMID:
42980531
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.